For the second year in a row, CILcare will be sponsoring this event dedicated to inner ear therapeutics development to further act towards better treatments and innovation for those suffering from hearing disorders.
Upcoming presentation: “Sensorineural Hearing Loss as a commorbidity of chronic inflammatory diseases”
Mathieu SCHUE, PhD, CILcare’s Project Director in Drug Development and Translational Research, will be giving an official presentation on June 21st at 9:15 am as part of the “Seeking Improved Outcomes for Patients with Inner Ear Diseases” session. This talk will be a great occasion to learn more about:
- The increased risk for sensorineural hearing loss as a complication of chronic inflammatory diseases
- Recent advances on identifying the underlying mechanisms
- Clinical perspectives, with the most promising pharmacological drug classes
Meet our team on our booth and book a tour to our US facility next-door!
Lise Byelyayeva, Business Developer, will welcome you on our booth to discuss your current and future projects. As our US facility is located a half hour drive from the event, we would be pleased to invite you for a meeting on our site, at CBSET. Feel free to contact us at email@example.com to book a meeting at our booth and in our facility in Lexington!
The Inner Ear Disorders Therapeutics Summit is a world-class event that gathers industry and academic experts from the hearing field, as well as innovative biopharmaceutical companies, to discuss the translation and clinical development of therapeutics that aim to treat inner disorders. Taking place in Boston, MA, on June 20-23 2022, this summit will gather all major key players in the hearing field to exchange on the clinical challenges and perspectives to treat sensorineural hearing loss.
CILcare is the world-leading R&D services company specialized in hearing disorders. Based in Montpellier, Boston, Paris, and Copenhagen, CILcare has become the one-stop partner for pharmaceutical industries, biotechs, medtechs, veterinary & nutraceutical companies, developing novel therapies for people with ear disorders. CILcare designs and performs pharmacokinetics, efficacy, and GLP ototoxicity studies to assess drugs, medical devices, cell & gene therapies, health food ingredients, on hearing loss, tinnitus, ototoxicity, and otitis.
See all Member News